Quick Takeaways
- MPM BioVentures 2014, L.P. filed SCHEDULE 13D/A for REPARE THERAPEUTICS INC. Common Shares (RPTX).
- Disclosed ownership: 6.3%.
- Date of event: 02 Jan 2025.
MPM BioVentures 2014, L.P. - 02 Jan 2025 SCHEDULE 13D/A Report for REPARE THERAPEUTICS INC. Common Shares (RPTX)
- Filing Manager
- MPM BioVentures 2014, L.P.
- Reporting Manager
- ANSBERT GADICKE
- Symbol
- RPTX
- Shares outstanding
- 42,198,921 shares
- Disclosed Ownership
- 2,658,532 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13D/A
- Filing time
- 06 Jan 2025, 16:49:09 UTC
- Date of event
- 02 Jan 2025
- Previous filing
- 26 Dec 2024
- Next filing
- 15 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MPM BioVentures 2014, L.P. disclosed 6.3% ownership in REPARE THERAPEUTICS INC. Common Shares (RPTX) on 02 Jan 2025."
What Changed
- Previous schedule filing date: 26 Dec 2024.
- Current filing was accepted on 06 Jan 2025, 16:49.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (11)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 3.3% | 1,394,624 | 1,394,624 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P. | 0001609492 |
| MPM BioVentures 2014 (B), L.P. | 0.2% | 93,019 | 93,019 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P | 0001609493 |
| MPM Asset Management Investors BV2014 LLC | 0.1% | 48,001 | 48,001 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC | 0001609495 |
| UBS Oncology Impact Fund L.P. | 2.6% | 1,122,888 | 1,122,888 | 0 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. | 0001691428 |
| MPM BioVentures 2014 GP LLC | 3.5% | 1,487,643 | 0 | 1,487,643 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC | 0001765091 |
| MPM BioVentures 2014 LLC | 3.6% | 1,535,644 | 0 | 1,535,644 | /s/ Ansbert Gadicke | Managing Director | 0001765021 |
| Oncology Impact Fund (Cayman) Management L.P. | 2.6% | 1,122,888 | 0 | 1,122,888 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P. | 0001721036 |
| MPM BioImpact LLC | 2.6% | 1,122,888 | 0 | 1,122,888 | /s/ Ansbert Gadicke | Managing Partner | 0001687078 |
| ANSBERT GADICKE | 6.3% | 2,658,532 | 0 | 2,658,532 | /s/ Ansbert Gadicke | Ansbert Gadicke | 0001134655 |
| LUKE EVNIN | 3.6% | 1,535,644 | 0 | 1,535,644 | /s/ Luke Evnin | Luke Evnin | 0001134657 |
| Todd Foley | 3.6% | 1,535,644 | 0 | 1,535,644 | /s/ Todd Foley | Todd Foley | 0001473930 |